Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
4499-40-5
Molecular formula
C12H21N5O3
Molecular weight
283.33 g/mol
Drug class
Theophylline salt complexmethylxanthine bronchodilator
Mechanism of action
Dissociates to release theophylline, which produces bronchodilation mainly through non-selective phosphodiesterase inhibition and adenosine-receptor antagonism, increasing intracellular cyclic AMP in bronchial smooth muscle. Choline is a counter-ion and does not confer a separate therapeutic mechanism.
Indications / reported uses
Historically used for bronchodilation in asthma and reversible obstructive airway disease in countries where products remain authorised; current use is limited by the narrow therapeutic index of theophylline and availability of safer alternatives
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Choline Theophyllinate Environmental Risk Assessment (ERA) (the Choline Theophyllinate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.